Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
xRj6U9faXVmnTwqv
Listen
